BridgeBio Pharma

BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for genetic diseases and cancers with clear genetic drivers. The enterprise developed acoramidis, a next-generation small-molecule transthyretin stabilizer engineered for patients with ATTR cardiomyopathy, alongside treatments for achondroplasia and rare metabolic disorders. By targeting the root genetic cause of conditions, BridgeBio Pharma delivers therapies directly to underserved patient populations.